A randomized, observer-blind Phase Ib study to identify formulations and vaccine schedules of a trivalent Group B Streptococcus vaccine for use in non-pregnant and pregnant women

Vaccine

Volumn 34, Issue 15, 2016, Pages 1786-1791

  Leroux Roels, Geert ^a   Maes, Cathy ^a   Willekens, Julie ^a   De Boever, Fien ^a   de Rooij, Richard ^b   Martell, Leah ^c,e   Bedell, Lisa ^c   Wittke, Frederick ^d   Slobod, Karen ^c,f   Dull, Peter ^c,g  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GLAXOSMITHKLINE   (Netherlands)

^c GLAXOSMITHKLINE   (United States)

^d GSK   (Italy)

^e Genzyme (A Sanofi company)   (United States)

^f CureVac GmbH   (Germany)

^g BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

Adjuvant; Group B streptococcus; Trivalent vaccine

Indexed keywords

ALUMINUM HYDROXIDE; ANTIBODY; CAPSULAR POLYSACCHARIDE; DIPHTHERIA TOXOID CRM197; GLYCOCONJUGATE; IMMUNOLOGICAL ADJUVANT; MIFAMURTIDE; PLACEBO; POLYSACCHARIDE; STREPTOCOCCUS VACCINE; TRIPLE VACCINE; TRIVALENT GROUP B STREPTOCOCCUS VACCINE; UNCLASSIFIED DRUG; BACTERIAL POLYSACCHARIDE; BACTERIUM ANTIBODY; VACCINE;

ADULT; ANTIBODY RESPONSE; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; GEOMETRIC MEAN CONCENTRATION; GROUP B STREPTOCOCCAL INFECTION; HEAT SENSATION; HUMAN; HUMAN EXPERIMENT; IMMUNIZATION; IMMUNOGENICITY; INFECTION; INFESTATION; INJECTION SITE REACTION; NORMAL HUMAN; PAIN; PARAMETERS; PHASE 1 CLINICAL TRIAL; PREGNANT WOMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; SIDE EFFECT; SINGLE BLIND PROCEDURE; STATISTICAL SIGNIFICANCE; BLOOD; CLINICAL TRIAL; HUMORAL IMMUNITY; IMMUNOLOGY; PREGNANCY; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIBODIES, BACTERIAL; FEMALE; HUMANS; IMMUNITY, HUMORAL; IMMUNIZATION SCHEDULE; POLYSACCHARIDES, BACTERIAL; PREGNANCY; SINGLE-BLIND METHOD; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS AGALACTIAE; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 84959562939     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.02.044     Document Type: Article

References (30)

1. Hickman M.E., Rench M.A., Ferrieri P., Baker C.J. Changing epidemiology of group B streptococcal colonization. Pediatrics 1999, 104(2 Pt 1):203-209.
2. Le Doare K., Heath P.T. An overview of global GBS epidemiology. Vaccine 2013, 31(Suppl. 4):D7-D12.
3. Shah B.A., Padbury J.F. Neonatal sepsis: an old problem with new insights. Virulence 2014, 5(1):170-178.
4. Thigpen M.C., Whitney C.G., Messonnier N.E., Zell E.R., Lynfield R., Hadler J.L., et al. Bacterial meningitis in the United States, 1998-2007. N Engl J Med 2011, 364(21):2016-2025.
5. Edmond K.M., Kortsalioudaki C., Scott S., Schrag S.J., Zaidi A.K.M., Cousens S., et al. Group B Streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis. Lancet 2012, 379(9815):547-556.
6. Verani J.R., McGee L., Schrag S.J. Prevention of perinatal Group B Streptococcal Disease: Revised Guidelines from CDC 2010, Available at: http://www.cdc.gov/mmwr/pdf/rr/rr5910.pdf. [accessed 26.10.15].
7. Verani J.R., Schrag S.J., Group B. streptococcal disease in infants: progress in prevention and continued challenges. Clin Perinatol 2010, 37(2):375-392.
8. Baker C.J. The spectrum of perinatal group B streptococcal disease. Vaccine 2013, 31(Suppl. 4):D3-D6.
9. Ohlsson A., Shah V.S. Intrapartum antibiotics for known maternal Group B streptococcal colonization. Cochrane Database Syst Rev 2014, 6:CD007467.
10. Berardi A., Rossi C., Lugli L., Creti R., Bacchi Reggiani M.L., Lanari M., et al. Group B streptococcus late-onset disease: 2003-2010. Pediatrics 2013, 131(2):e361-e368.
11. Baker C.J., Carey V.J., Rench M.A., Edwards M.S., Hillier S.L., Kasper D.L., et al. Maternal antibody at delivery protects neonates from early onset Group B streptococcal disease. J Infect Dis 2014, 209(5):781-788.
12. Lin F.Y.C., Philips J.B., Azimi P.H., Weisman L.E., Clark P., Rhoads G.G., et al. Level of maternal antibody required to protect neonates against early-onset disease caused by group B streptococcus type Ia: a multicenter, seroepidemiology study. J Infect Dis 2001, 184(8):1022-1028.
13. Lin F.Y.C., Weisman L.E., Azimi P.H., Philips J.B., Clark P., Regan J., et al. Level of maternal IgG anti-group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen. J Infect Dis 2004, 190(5):928-934.
14. Kaspar D.L., Paoletti L.C., Wessels M.R., Guttormsen H.K., Carey V.J., Jennings H.J., et al. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest 1996, 98(10):2308-2314.
15. Edwards M.S., Lane H.J., Hillier S.L., Rench M.A., Baker C.J. Persistence of functional antibodies to group B streptococcal capsular polysaccharides following immunization with glycoconjugate vaccines. Vaccine 2012, 30(28):4123-4126.
16. Baker C.J., Rench M.A., Paoletti L.C., Edwards M.S. Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adults. Vaccine 2007, 25(1):55-63.
17. Black S., Margarit I., Rappuoli R. Preventing newborn infection with maternal immunization. Sci Transl Med 2013, 5(195).
18. Madhi S.A., Dangor Z., Heath P.T., Schrag S., Izu A., Sobanjo-Ter Meulen A., et al. Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants. Vaccine 2013, 31(Suppl. 4):D52-D57.
19. Phares C.R., Lynfield R., Farley M.M., Mohle-Boetani J., Harrison L.H., Petit S., et al. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA 2008, 299(17):2056-2065.
20. Khurana S., Verma N., Yewdell J.W., Hilbert A.K., Castellino F., Lattanzi M., et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med 2011, 3(85).
21. Donders G.G.G., Halperin S.A., Devlieger R., Baker S., Forte P., Wittke F., et al. Maternal immunisation with a trivalent glycoconjugate GBS vaccine - a phase II randomised study. Obstet Gynecol 2016, 127(2):213-221.
22. Jordan H.T., Farley M.M., Craig A., Mohle-Boatani J., Harrison L.H., Petit S., et al. Revisiting the need for vaccine prevention of late-onset neonatal group B streptococcal disease a multistate, population-based analysis. Pediatr Infect Dis J 2008, 27(12):1057-1064.
23. Baker C. Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine. Vaccine 2003, 21(24):3468-3472.
24. Chen V.L., Avci F.Y., Kasper D.L. A maternal vaccine against group B Streptococcus: past, present, and future. Vaccine 2013, 31(Suppl. 4):D13-D19.
25. Kotloff K.L., Fattom A., Basham L., Hawwari A., Harkonen S., Edelman R. Safety and immunogenicity of a tetravalent group B streptococcal polysaccharide vaccine in healthy adults. Vaccine 1996, 14(5):446-450.
26. Baker C.J., Paoletti L.C., Wessels M.R., Guttormsen H.K., Rench M.A., Hickman M.E., et al. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. J Infect Dis 1999, 179(1):142-150.
27. Baker C.J., Paoletti L.C., Rench M.A., Guttormsen H.K., Carey V.J., Hickman M.E., et al. Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women. J Infect Dis 2000, 182(4):1129-1138.
28. van Damme P., Kafeja F., Anemona A., Basile V., Hilbert A.K., De Coster I., et al. Safety, immunogenicity and dose ranging of a new Vi-CRM(1)(9)(7) conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults. PLoS One 2011, 6(9):e25398.
29. Madhi S.A., Cutland C.L., Jose L., Koen A., Govender N., Stenglein S., et al. Safety and immunogenicity of an investigational trivalent Group B Streptococcus vaccine in healthy non-pregnant and pregnant women - a Phase IB/II trial. Proceedings of the 14th European Congress of Perinatal Medicine, June 4-7th 2014.
30. Paoletti L.C., Rench M.A., Kasper D.L., Molrine D., Ambrosino D., Baker C.J. Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines. Infect Immun 2001, 69(11):6696-6701.